FDA Psychopharmacologic Drugs Advisory Committee Meeting Briefing On Probuphine

This document released on January 12, 2016, is a new drug application briefing discussed by an advisory committee of the United States Food and Drug Administration (FDA). The application is for Probuphine, which is an implanted rod that delivers a continuous dose of buprenorphine as opioid dependence maintenance treatment. The advisory committee recommended that the FDA approve Probuphine . . .